Werewolf Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
Condensed Consolidated Statements of Cash Flows (unaudited)
(amounts in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities: | ||
| Net loss | $(13,532) | $(18,089) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 929 | 2,006 |
| Depreciation expense | 398 | 426 |
| Non-cash interest expense | 595 | 490 |
| Non-cash lease expense | 218 | 188 |
| Change in fair value of derivative liability | (674) | (171) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other assets | 161 | 131 |
| Accounts payable, accrued expenses and other liabilities | 1,923 | (3,366) |
| Operating lease liability | (615) | (563) |
| Net cash used in operating activities | (10,597) | (18,948) |
| Net decrease in cash, cash equivalents and restricted cash and cash equivalents | (10,597) | (18,948) |
| Cash, cash equivalents and restricted cash and cash equivalents—beginning of period | 57,951 | 112,215 |
| Cash, cash equivalents and restricted cash and cash equivalents—end of period | $47,354 | $93,267 |
| Reconciliation of cash, cash equivalents and restricted cash and cash equivalents to the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $46,450 | $92,042 |
| Prepaid expenses and other current assets | 904 | 334 |
| Restricted cash and cash equivalents, net of current portion | — | 891 |
| Total cash, cash equivalents and restricted cash and cash equivalents | $47,354 | $93,267 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $773 | $773 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Issuance costs in accounts payable and accrued expenses | $75 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.